Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Webster Bank N. A.

Webster Bank N. A. raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 17.9% in the first quarter, Holdings Channel.com reports. The fund owned 3,854 shares of the medical research company’s stock after purchasing an additional 584 shares during the period. Webster Bank N. A.’s holdings in Amgen were worth $1,096,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Diversified Trust Co boosted its stake in shares of Amgen by 76.8% in the fourth quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock valued at $10,857,000 after purchasing an additional 16,376 shares during the period. Provence Wealth Management Group lifted its stake in Amgen by 11.9% in the fourth quarter. Provence Wealth Management Group now owns 1,445 shares of the medical research company’s stock worth $416,000 after acquiring an additional 154 shares during the last quarter. Kinsale Capital Group Inc. lifted its stake in Amgen by 33.0% in the fourth quarter. Kinsale Capital Group Inc. now owns 11,348 shares of the medical research company’s stock worth $3,269,000 after acquiring an additional 2,814 shares during the last quarter. Global Wealth Management Investment Advisory Inc. raised its holdings in Amgen by 2.4% during the fourth quarter. Global Wealth Management Investment Advisory Inc. now owns 4,733 shares of the medical research company’s stock worth $1,363,000 after purchasing an additional 109 shares in the last quarter. Finally, Traynor Capital Management Inc. raised its holdings in Amgen by 9.5% during the fourth quarter. Traynor Capital Management Inc. now owns 18,941 shares of the medical research company’s stock worth $5,455,000 after purchasing an additional 1,650 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 2,117 shares of the firm’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total value of $662,811.53. Following the transaction, the senior vice president now owns 9,883 shares in the company, valued at $3,094,268.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.69% of the company’s stock.

Amgen Trading Down 0.4 %

Shares of Amgen stock traded down $1.24 during mid-day trading on Friday, hitting $312.45. 3,518,174 shares of the stock were exchanged, compared to its average volume of 2,437,626. Amgen Inc. has a twelve month low of $218.44 and a twelve month high of $329.72. The stock has a market capitalization of $167.61 billion, a price-to-earnings ratio of 44.64, a price-to-earnings-growth ratio of 2.83 and a beta of 0.60. The company has a 50-day simple moving average of $301.56 and a 200 day simple moving average of $292.10. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, topping the consensus estimate of $3.76 by $0.20. The business had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The company’s revenue was up 22.0% on a year-over-year basis. During the same period in the prior year, the firm posted $3.98 EPS. Research analysts forecast that Amgen Inc. will post 19.47 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on AMGN shares. TD Cowen cut their target price on shares of Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a report on Wednesday, April 17th. Barclays raised shares of Amgen from an “underweight” rating to an “equal weight” rating and lifted their target price for the company from $230.00 to $300.00 in a report on Friday, May 3rd. StockNews.com raised shares of Amgen from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Raymond James assumed coverage on shares of Amgen in a research note on Thursday, March 28th. They issued a “market perform” rating on the stock. Finally, William Blair raised shares of Amgen from a “market perform” rating to an “outperform” rating in a research note on Friday, May 3rd. Ten equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $307.35.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.